{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:58:32Z","timestamp":1785517112414,"version":"3.56.0"},"reference-count":17,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ocul Oncol Pathol"],"abstract":"<jats:p>Introduction: This single-institution study characterizes outcomes in periocular sebaceous carcinoma and evaluates whether treatment delay is associated with orbital exenteration. Methods: Retrospective case series of all patients diagnosed with primary periocular sebaceous carcinoma between January 1, 2000, and December 31, 2022, at a single academic institution. Clinical, histopathologic, treatment, and outcome data were analyzed. Association between time to treatment and orbital exenteration was assessed using logistic regression. Results: The study included 25 patients (median age 76.6 years). Prior misdiagnosis occurred in 21 (84%), most commonly as chalazia (n = 7) or blepharitis (n = 6). Most tumors were AJCC T1, with predominantly poor or moderate differentiation. Mean time from presentation-to-treatment was 5.67 months (range 0.26\u201328.52 months), with a subset experiencing prolonged delays. Most patients underwent wide local excision (52%) or Mohs surgery (32%), with 4 (16%) requiring exenteration. Each 3-month increase in time to treatment was associated with 16% greater odds of orbital exenteration (OR: 1.16, 95% CI: 1.01\u20131.38; p = 0.042). Demographic and socioeconomic variables were not associated with differences in delays or outcomes. Median follow-up was 43 months, during which visual acuity remained stable in non-exenterated patients (median logMAR change \u22120.125). Local tumor recurrence occurred in 4 (16%) at a median of 26.46 months. Overall survival was 54.2% at 10 years, with no deaths attributed to sebaceous carcinoma. Conclusion: Treatment delay was associated with increased odds of orbital exenteration and not with measured socioeconomic factors. These findings suggest a potential relationship between time-to-treatment and extent of surgical management, with possible implications for vision preservation and quality of life.<\/jats:p>","DOI":"10.1159\/000553091","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:01:26Z","timestamp":1781798486000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Delay and Risk of Orbital Exenteration in Periocular Sebaceous Carcinoma"],"prefix":"10.1159","author":[{"given":"Grant M.","family":"Welk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Israilevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4284","authenticated-orcid":false,"given":"Lauren A.","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.","family":"Tooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302443"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319789"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.07.031"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4087"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-15775-z"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000002660"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26774"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.10.4"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.053"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23952"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.79"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14552"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.046"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20220369"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0b013e31816d925f"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0756-9"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2022.2106781"}],"container-title":["Ocular Oncology and Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000553091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:01:00Z","timestamp":1785513660000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000553091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1159\/000553091","archive":["Portico"],"relation":{},"ISSN":["2296-4681","2296-4657"],"issn-type":[{"value":"2296-4681","type":"print"},{"value":"2296-4657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}